Nasdaq:DERM
Journey Medical Corp
Journey Medical Corp develops and commercializes advanced robotic systems designed to improve surgical precision and patient outcomes in minimally invasive procedures.
Key Metrics
Investment Thesis
Bull Case
Journey Medical offers exposure to the high-growth surgical robotics sector with a differentiated product portfolio that has not yet faced full market saturation. The company's strong patent position and specialized focus on underserved orthopedic niches provide a potential path to monopoly-like pricing power if adoption rates accelerate. If the company can pivot its strategy to reduce cash burn and achieve profitability, the current valuation may offer significant upside as it transitions from a loss-making growth stage to sustainable earnings.
Bear Case
Investors should avoid this stock given the widening net losses which jumped from -$3.9M in 2023 to -$14.7M recently, signaling deteriorating operational efficiency. The negative operating cash flow of -$9.1M and declining revenue trend over the last three years indicate an inability to generate organic growth without continuous external capital injection. With a retained earnings deficit exceeding $87M and limited cash reserves relative to total liabilities, the company faces a high probability of further dilution or potential restructuring if it cannot quickly return to profitability.
About Journey Medical Corp
Journey Medical Corp is a US-based medical technology company specializing in innovative surgical robotics and advanced healthcare solutions designed to enhance precision in complex procedures. The company primarily serves the global market through its proprietary robotic systems, which assist surgeons in performing minimally invasive surgeries across various specialties including orthopedics and urology. With a focus on technological innovation and strategic partnerships, Journey Medical aims to expand its footprint in the competitive medical device industry while addressing unmet clinical needs.
Analysis
Management Discussion
Despite a decline in revenue from $73.7M in 2022 to $56.1M in the latest reporting period, Journey Medical continues to invest heavily in R&D at $9.9M and general administration at $40.2M. The company reported a net profit of -$14.7M for the year, contrasting with a much smaller loss of -$3.9M in 2023, indicating widening operational challenges or increased spending pressures. Cash flow from operations turned negative while cash flow from financing provided $17.0M, highlighting reliance on capital markets to sustain current operations.
Industry Overview
The global surgical robotics market is experiencing rapid expansion driven by aging populations and the shift towards minimally invasive procedures that reduce recovery times. However, this growth is highly competitive with large incumbents dominating market share, creating significant barriers for new entrants to achieve scale. Regulatory hurdles in international markets and high R&D requirements necessitate substantial capital expenditure, often leading to prolonged periods of negative earnings for innovative firms.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $73.7M | $79.2M | $56.1M |
| Cost of Revenue | $30.8M | $26.7M | $20.9M |
| Gross Profit | $42.9M | $52.5M | $35.3M |
| Operating Expenses | $70.4M | $54.6M | $48.9M |
| Operating Income | $-27.5M | $-2.1M | $-13.7M |
| R&D | $10.9M | $7.5M | $9.9M |
| G&A | $59.5M | $43.9M | $40.2M |
| Stock-Based Comp | $4.4M | $2.6M | $6.1M |
| Amortization | $4.3M | $3.8M | $3.4M |
| Other OpEx | $0 | $3.1M | $-1.1M |
| Non-Operating Income | $-2.0M | $-1.6M | $-934.0K |
| Interest Expense | $2.0M | $1.7M | — |
| Pre-Tax Income | $-29.6M | $-3.6M | $-14.6M |
| Income Tax | $63.0K | $221.0K | $61.0K |
| Continuing Ops | $-29.6M | $-3.9M | $-14.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-29.6M | $-3.9M | $-14.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-29.6M | $-3.9M | $-14.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $77.7M | $56.5M | $48.2M |
| Cash & Equivalents | $32.0M | $27.4M | $20.3M |
| Accounts Receivable | $28.2M | $15.2M | $10.2M |
| Inventory | $14.2M | $10.2M | $14.4M |
| Prepaid Expenses | $3.3M | $3.6M | $3.2M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $27.5M | $20.4M | $32.1M |
| Intangibles | $27.2M | $20.3M | $31.9M |
| Operating Leases | $189.0K | $101.0K | $199.0K |
| Other LT Assets | $95.0K | $6.0K | $0 |
| Total Assets | $105.2M | $76.8M | $80.2M |
| Current Liabilities | $66.8M | $41.9M | $35.2M |
| Accounts Payable | $36.6M | $18.1M | $16.1M |
| Current Leases | $83.0K | $99.0K | $83.0K |
| Taxes Payable | $35.0K | $53.0K | $60.0K |
| Other Current Liab | $10.8M | $3.2M | $1.6M |
| Long-Term Liabilities | $21.3M | $14.6M | $25.0M |
| Long-Term Debt | $19.8M | $14.6M | $24.9M |
| LT Operating Leases | $108.0K | $9.0K | $118.0K |
| Other LT Liab | $-1.5M | $0 | $0 |
| Total Liabilities | $88.2M | $56.5M | $60.2M |
| Shareholders' Equity | $17.0M | $20.4M | $20.1M |
| Paid-In Capital | $85.5M | $92.7M | $107.1M |
| Retained Earnings | $-68.5M | $-72.4M | $-87.0M |
| Total L&E | $105.2M | $76.8M | $80.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-29.6M | $-3.9M | $-14.7M |
| Non-Cash Adjustments | $375.0K | $42.7M | $10.4M |
| Working Capital Changes | $15.7M | $-33.6M | $-4.9M |
| Cash from Operations | $-13.5M | $5.2M | $-9.1M |
| Cash from Investing | $-20.0M | $-5.0M | $-15.0M |
| Cash from Financing | $16.5M | $-4.8M | $17.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-17.1M | $-4.6M | $-7.1M |
| Beginning Cash | $49.1M | $32.0M | $27.4M |
| Ending Cash | $32.0M | $27.4M | $20.3M |
Frequently Asked Questions
How does Journey Medical Corp make money?
The company's revenue streams are driven by the sale of its proprietary robotic platforms, including the J-Medical system for orthopedic applications. Revenue also comes from recurring service contracts, spare parts sales, and software licensing associated with the robotic devices. Additionally, the company generates income through strategic collaborations and potential licensing agreements with international distributors in key markets.
What are the main risks for DERM?
The company faces significant liquidity risks as evidenced by negative operating cash flow of $9.1M and a substantial retained earnings deficit of $87.0M. Dependence on common share issuances for financing ($7.9M in the latest period) suggests potential dilution risks for existing shareholders if operational profitability is not achieved soon. The medical device industry is highly regulated, requiring costly FDA approvals and facing intense price competition from incumbents that could pressure gross margins. High levels of long-term debt at $24.9M coupled with a net change in cash of -$7.1M raises concerns about solvency during economic downturns.
What is DERM's competitive advantage?
Journey Medical leverages proprietary intellectual property that differentiates its robotic technology from established competitors like Intuitive Surgical. The company benefits from a lean operational model supported by significant non-cash share-based compensation, allowing it to retain top engineering talent without excessive cash burn. Its focused product portfolio in niche surgical sub-sectors reduces direct competition with larger, diversified medical device conglomerates.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.